• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对基于达雷妥尤单抗的化疗反应不佳的高危非分泌型多发性骨髓瘤

High-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy.

作者信息

Khanal Surendra, Rizvi Rameela, March Christopher

机构信息

Internal Medicine, Piedmont Athens Regional, Athens, USA.

出版信息

Cureus. 2025 Feb 7;17(2):e78665. doi: 10.7759/cureus.78665. eCollection 2025 Feb.

DOI:10.7759/cureus.78665
PMID:40065868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11891464/
Abstract

Nonsecretory multiple myeloma (NSMM) is the variant of multiple myeloma defined by no detectable M protein secretion in serum or urine electrophoresis. Due to the lack of detectable M spike, diagnosis is often challenging and relies on bone marrow studies. As studies specifically focusing on NSMM are lacking, the current treatment guidelines are based on studies in secretory multiple myeloma. In this case report, we describe a 77-year-old female patient with a typical presentation of NSMM who did not respond to a chemotherapy regimen based on daratumumab.

摘要

非分泌型多发性骨髓瘤(NSMM)是多发性骨髓瘤的一种变体,其定义为血清或尿液电泳中未检测到M蛋白分泌。由于缺乏可检测到的M峰,诊断往往具有挑战性,且依赖于骨髓检查。由于缺乏专门针对NSMM的研究,目前的治疗指南是基于分泌型多发性骨髓瘤的研究制定的。在本病例报告中,我们描述了一名77岁的女性患者,她具有NSMM的典型表现,对基于达雷妥尤单抗的化疗方案无反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/afeb75705ffb/cureus-0017-00000078665-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/035e119ff1fe/cureus-0017-00000078665-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/e3471d8f8f68/cureus-0017-00000078665-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/f52019075c79/cureus-0017-00000078665-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/afeb75705ffb/cureus-0017-00000078665-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/035e119ff1fe/cureus-0017-00000078665-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/e3471d8f8f68/cureus-0017-00000078665-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/f52019075c79/cureus-0017-00000078665-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdee/11891464/afeb75705ffb/cureus-0017-00000078665-i04.jpg

相似文献

1
High-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy.对基于达雷妥尤单抗的化疗反应不佳的高危非分泌型多发性骨髓瘤
Cureus. 2025 Feb 7;17(2):e78665. doi: 10.7759/cureus.78665. eCollection 2025 Feb.
2
Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.非分泌型多发性骨髓瘤与分泌型多发性骨髓瘤的结局和特征比较:来自中国的回顾性多中心研究。
BMC Cancer. 2023 Oct 2;23(1):930. doi: 10.1186/s12885-023-11223-4.
3
A Rare Case of Nonsecretory Multiple Myeloma in Lagos, Nigeria: A Case Report and Literature Review.尼日利亚拉各斯非分泌型多发性骨髓瘤1例罕见病例:病例报告及文献综述
Case Rep Med. 2015;2015:648069. doi: 10.1155/2015/648069. Epub 2015 Nov 15.
4
The Missing M Band: Is it Really Non Secretory Multiple Myeloma?缺失的M带:它真的是非分泌型多发性骨髓瘤吗?
EJIFCC. 2025 Feb 28;36(1):74-82. eCollection 2025 Mar.
5
Nonsecretory Multiple Myeloma Presenting as Recurrent Vertebral Compression Fractures in an Older Male Patient.一名老年男性患者以复发性椎体压缩骨折为表现的非分泌型多发性骨髓瘤
Ann Geriatr Med Res. 2018 Jun;22(2):98-101. doi: 10.4235/agmr.2018.22.2.98. Epub 2018 Jun 30.
6
Nonsecretory multiple myeloma.非分泌型多发性骨髓瘤
South Med J. 2002 Jul;95(7):761-4.
7
Calorimetric markers of Bence Jones and nonsecretory multiple myeloma serum proteome.Bence Jones 和非分泌型多发性骨髓瘤血清蛋白质组的量热学标志物。
Anal Chem. 2014 Dec 16;86(24):12355-61. doi: 10.1021/ac503677d. Epub 2014 Dec 5.
8
Nonsecretory Multiple Myeloma and AL Amyloidosis Presenting with Nephrotic Range Proteinuria.以肾病范围蛋白尿为表现的非分泌型多发性骨髓瘤和AL淀粉样变性
Case Rep Nephrol. 2015;2015:635974. doi: 10.1155/2015/635974. Epub 2015 May 21.
9
[Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].非分泌型多发性骨髓瘤血清游离轻链的检测及其临床意义
Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):113-6.
10
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.每周卡非佐米、来那度胺、地塞米松和达雷妥尤单抗联合治疗新诊断多发性骨髓瘤患者的安全性和有效性:MANHATTAN 非随机临床试验。
JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.

本文引用的文献

1
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
2
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.评估达雷妥尤单抗治疗伴有高危细胞遗传学因素的多发性骨髓瘤患者的疗效:系统评价和荟萃分析。
JAMA Oncol. 2020 Nov 1;6(11):1759-1765. doi: 10.1001/jamaoncol.2020.4338.
3
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
SWOG S0777 随机 III 期试验的长期随访:硼替佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗未经治疗的多发性骨髓瘤且无立即进行自体干细胞移植(ASCT)意向的患者。
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
4
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.寡分泌型和非分泌型多发性骨髓瘤的临床特征和转归。
Ann Hematol. 2020 Jun;99(6):1251-1255. doi: 10.1007/s00277-020-03984-w. Epub 2020 Apr 19.
5
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.国际骨髓瘤工作组关于单克隆浆细胞疾病影像学的共识建议。
Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2.
6
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.多发性骨髓瘤全球负担:2016 年全球疾病负担研究的系统分析。
JAMA Oncol. 2018 Sep 1;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128.
7
Multiple myeloma: patient outcomes in real-world practice.多发性骨髓瘤:真实世界实践中的患者结局
Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.
8
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.高危细胞遗传学特征的多发性骨髓瘤的治疗:国际骨髓瘤工作组共识
Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.
9
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
10
Clinical course and prognosis of non-secretory multiple myeloma.非分泌型多发性骨髓瘤的临床病程及预后
Eur J Haematol. 2015 Jul;95(1):57-64. doi: 10.1111/ejh.12478. Epub 2015 Jan 21.